XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 31.84

+0.1%

1:11 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Olu Emuleomo who started this subject	7/3/2004 2:31:08 PM
From: Robert K.	of 17367

Or how about this POST raptiva article that talks about biologic risks. Note the EXCLUSION >Precautions with biologic agents Although these new biologic agents appear to act with greater target specificity than the systemic immunosuppressives that are currently available, questions remain regarding their safety in patients with ongoing or latent infection, immunosuppression or malignancy. For example, TNF- appears to be critical for the maintenance of granulomatous-type responses, and the TNF- inhibitors infliximab and etanercept have been associated with tuberculosis infection or reactivation.41 Since both alefacept and siplizumab result in antibody-mediated cytotoxicity of activated memory T-cells, treatment with these agents can cause a significant drop in T-cell counts.8,20 Furthermore, as many of these agents are new on the market, the relevance of potential associated adverse events such as demyelinating diseases has not yet been established.42 The safety and efficacy of vaccinations is also uncertain with the immunosuppressive nature of these medications. Overall, the projected high cost poses the greatest potential limitation to the wide availability and accessibility of these agents

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next